Moors & Cabot’s West Pharmaceutical WST Stock Holding History

Moors & Cabot’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	-$6K	–	980
2021 Q4	$6K	Buy	+1	New	+$430	﹤0.01%	871

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moors & Cabot's WST Position: Q3 2022 in Review

Moors & Cabot sold out of West Pharmaceutical (WST) in Q3 2022, closing a stake of 844 shares — an estimated $255K sold.

Moors & Cabot first reported a position in WST in Q4 2021 and held it in 3 quarters. The position peaked at $349K in Q1 2022. 638 funds tracked by Wall St. Rank hold WST as of Q3 2022.

Moors & Cabot reported no remaining West Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Moors & Cabot sold 844 West Pharmaceutical shares in Q3 2022, an estimated $255K.
Moors & Cabot first reported a position in West Pharmaceutical in Q4 2021 and held it in 3 quarters.
Moors & Cabot's West Pharmaceutical position peaked at $349K in Q1 2022.
638 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on Moors & Cabot's 13F filing for Q3 2022, filed 8 Nov 2022.